RBC Capital Maintains Outperform on Globus Medical, Lowers Price Target to $85
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Kendall Au maintains Globus Medical (NYSE:GMED) with a Outperform and lowers the price target from $115 to $85.
RBC Capital analyst Kendall Au maintains Globus Medical (NYSE:GMED) with a Outperform and lowers the price target from $115 to $85.